founders – en

TEAM

Birkenfeld neu

PROF. DR. MED. ANDREAS BIRKENFELD

SCIENTIFIC FOUNDER

 

Chair of Medicine and Director of the Department of Diabetology, Endocrinology and Nephrology, University Clinic Tübingen

  • Director Dept. for Diabetology, Endocrinology, Nephrology, University Clinic Tübingen; Chair and Full Professor of Diabetology, Endocrinology, Nephrology, University Tübingen; Director Institute of Diabetes Research and Metabolic Diseases (IDM) Helmholtz Center Munich; Director of the Southwest German Diabetes Center (SWDZ) University Tübingen; Board of Directors Interfaculty Centre for Pharmacogenomics and Pharma Research (ICEPHA) University Tübingen; Chair of Clinical Study Board German Center for Diabetes Research; Speaker German Center for Diabetes Research (DZD e.V.); Board, AG Diabetes & Heart, German Diabetes Association (DDG); Reader (~ Associate Professor) Dept. of Diabetology King’s College London UK
  • Previous Positions: Postdoctoral Fellow of the DFG, Yale University with Gerald I Shulman; DFG-Group Leader ‘Energy Metabolism’ Charité-Berlin; Hans A. Krebs Professor of Therapy & Pathophysiology of Diabetes Charité-Berlin; Associate Professor of Metabolic Vascular Medicine Medical Faculty of the Technical University Dresden, Chair of Dept. of Metabolic Vascular Medicine University Clinic Dresden
  • Clinical expertise: Board certified specialist in Internal Medicine, Board certified specialist in Diabetes Medicine, Endocrinology and Lipidology (DGFF), Research group leader focusing on understanding molecular, cellular and clinical mechanisms of the regulation of energy homeostasis

Foto Verena Müller; © Universitätsklinikum Tübingen

Picture3

PROF. DR. MED. JENS JORDAN

SCIENTIFIC FOUNDER

 

Head of Institute of Aerospace Medicine, Cologne

  • Director, Institute of Aerospace Medicine, German Aerospace Center (DLR) and University of Cologne
  • Previous positions: Director Institute for Clinical Pharmacology, Medical School Hannover (MHH); Director of the Franz-Volhard Center for Clinical Research Charité Berlin; Clinical Working Group Leader at the Max-Delbrück Centrum (MDC) Berlin
  • Clinical expertise: board certified clinical pharmacologist and internist specialized in cardiovascular and metabolic disease management, research group leader with focus on mechanisms and causes of obesity-associated metabolic and cardiovascular disease
bearb_IMG_5583

MARCO JANEZIC

MANAGING DIRECTOR & CO-FOUNDER

  • Managing Director and co-founder of Eternygen, CEO and Founding Partner Blue Ribbon Partners, Managing Director Life Science Factory Göttingen, Associate of the Creative Destruction Lab Oxford (Health and AI streams)
  • Marco has started a dozen companies, a big proportion of which in the biotech space and did 4 exits (incl. a silicon valley exit)
  • Previous positions: entrepreneur and investor with activities across multiple sectors, including Biotech/LifeSciences (Chazim AkroMab, SmartBax),  IT (IntraWorlds),  Media (vertical network media, wunder media), Services (Clevis Group) and Impact/Social Investments (Talents4Good, Auticon, Media4Care); positions  in investment banking in the UK and management consultancy in Germany, Lecturer on entrepreneurship at different universities
  • Educational background: MA in Theoretical Physics and Philosophy University of Oxford
Picture5

DR. GRIT ZAHN

HEAD OF SCIENCE

  • Head of Research of Eternygen GmbH
  • Grit has more than 20 Years experience in drug development and was part of one of Germany’s first and most high-profile BioTech successes
  • Previous positions: Senior Director Lead Discovery Biology at Jerini AG, Project leader at Jerini Ophthalmic Inc. New York, Head of Project Management R&D ipal GmbH, Researcher at Charité University Hospital in Berlin
  • Educational background: PhD in Biochemistry from Humboldt University Berlin
Elisabeth_Karg

DR. ELISABETH KARG

OPERATIONS & FINANCE

  • Operations & Finance Eternygen, Venture Manager at Blue Ribbon Partners
  • Elisabeth has learned to love -omics based approaches during her PhD and now oversees the Operations and Finances at Eternygen and engages in numerous life science entrepreneurial activities as a Venture Manager at Blue Ribbon Partners
  • Previous Positions: Research positions at LMU Munich, Research Intern at Carnegie Institution for Science Stanford USA
  • Educational background: PhD in Biology from LMU Munich

BOARD

Christian Schetter

DR. CHRISTIAN SCHETTER

CHAIRMAN OF THE BOARD

  • Managing Director Arix Bioscience
  • Board & Advisory positions: Executive Chairman STipe Therapeutics, Non-Executive Director Atox Bio, Twelve Bio, Pyxis Oncology
  • Previous positions: CEO Rigontec GmbH; President and CEO Neovii Biotech, previously Fresenius Biotech.; Senior Vice President, European Operations Coley Pharmaceutical Group; Managing Director Coley GmbH
  • Educational background: PhD from the University of Cologne, postdoctoral research in oncology and virology at the Scripps Research Institute in La Jolla, California, USA and Max-Planck-Institute for Biochemistry, Martinsried.
ibb_ventures_Ute-Mercker_p

UTE MERCKER

BOARD MEMBER

 

Investment Director IBB Ventures

  • Prokuristin / Investment Director at IBB Ventures
  • Current Board seats: Omeicos Therapeutics, Selfapy,  Eternygen, AIgnostics, Newsenselab
  • Longtime experience in early stage Venture Capital investments with healthcare focus:  Digital Health as well as Biotech & MedTech companies like Jerini, Scienion and Scopis
  • Educational background: MBA from the Freie Universität Berlin
Kyp Sirinakis

KYPARISSIA SIRINAKIS

BOARD MEMBER

 

Managing Partner Epidarex Capital

  • Co-founder and Managing Partner of Epidarex Capital
  • Current Board positions: Slate Biosciences Inc, Eternygen
  • Previous board positions: Harpoon Medical, Confluence Life Science, Nodthera, Sirakoss
  • Previous positions: senior management MASA Life Science Ventures (MLSV), CFO Oncologix, numerous directorships of start-up companies
  • Educational background: Graduate of Boston College’s School of Management Honors Program, certified Public Accountant in Maryland
Klaus Schollmeier 2

DR. KLAUS SCHOLLMEIER

BOARD MEMBER

 

CEO KCS-GmbH

  • CEO of KCS-GmbH
  • Board & Advisory positions: Tacalyx (Germany), Modra Pharmaceuticals (Netherlands), Anergis Pharma (Switzerland), Affiris Pharma (Austria) and Eternygen (Germany).
  • Previous positions: CEO SuppreMol GmbH, CEO Santhera Pharmaceuticals AG, several positions at BASF, Knoll and Abbott.
  • Educational background: PhD in Biology from the University of Düsseldorf, Germany
Cord Dohrmann

DR. CORD DOHRMANN

BOARD MEMBER

 

Chief Scientific Officer Evotec AG

  • Chief Scientific Officer and Member of the Management of Evotec SE
  • Board positions: Breakpoint Therapeutics, Facio Therapies, Immunitas, Eternygen
  • Advisory positions: Advisor to the German Council of Science and Humanities, the European Commission, the Max-Planck-Institute as well as various venture capital firms
  • Previous positions: CEO of DeveloGen, Researcher at the Massachusetts General Hospital in Boston and at the Duke University, Durham, USA
  • Educational background: PhD from Harvard Medical School in Boston, USA

OBSERVERS

Molecule_white_300

PETER FINAN, PHD

KEY ADVISOR

 

Venture Partner Epidarex GmbH

  • Venture Partner Epidarex Capital
  • Board & Advisory positions: Boards of Directors Clyde Biosciences, Enterprise Therapeutics, Leucid Bio, Epidarex Exeed, Epsilogen, Eternygen, Topas Therapeutics, Lunac Therapeutics
  • Previous positions: Global Head of the Respiratory Disease Area and Site Head Novartis Institute of BioMedical Research UK, research positions at Cancer Research UK and the Yamanouchi Research Institute (now Astellas), Head of Biology Karus Therapeutics.
  • Educational background: BSc and PhD in Biochemistry and Molecular Biology University of Leeds
Molecule_white_300

DR. KURT SCHWARZ

OBSERVER

 

Founder & Managing Director Leifina GmbH

  • Founder and Managing Director Leifina GmbH, investor and business angel of various biotech companies
  • Board positions: several board seats
  • Previous positions: Merck & Co. (New Jersey and german subsidiary), Research Fellow at Harvard Medical School and Massachusetts General Hospital Boston
  • Educational background: MD University of Heidelberg, PhD in Experimental Pharmacology

ADVISORS

Unknown

DR. CHRISTOPH GIBSON

ADVISOR

 

Director and head of Medicinal Chemistry department at AnalytiCon GmbH, Potsdam, Germany

  • Director and Head of Medicinal Chemistry AnalytiCon
  • Previous positions: Head of Development and Project Management ViroLogik, Director Medicinal Chemistry Jerini AG, postdoctoral fellow Institute for Organic Chemistry and Biochemistry Technical University of Munich and The Scripps Research Institute in La Jolla, California
  • Educational background: PhD in chemistry Technical University of Munich
schnorrenberg 1

PROF. DR. GERD SCHNORRENBERG

ADVISOR

 

  • Scientific advisor with extensive experience in pharmaceutical research and development in several therapeutic areas
  • Previous positions: Head of Research Germany Boehringer Ingelheim Pharma GmbH & Co KG; lecturer in medicinal chemistry at Johannes Gutenberg University Mainz, honorary professorship from the German federal State of Rheinland-Pfalz; sabbatical at the University of California in San Diego and at Massachusetts Institute of Technology.
  • Educational background: Diploma in Chemistry, PhD University of Bonn